Airdate: Tuesday, November 8, 2022 Season: 1 Episode: 10
Guest: Chris Rand
On this episode of #IndustryInsights, we spoke with Chris Rand, MSc, Sales and Marketing Manager at Aurora Scientific. Chris delves into the start and evolution of Aurora Scientific, and their journey within the preclinical research world. He also discusses their advance into the neuroscience space, plus some insight into how the company may expand in the near future. Listen to find out what exciting new Industry Insights are coming from Aurora Scientific!
Read the full blog and watch the interview here.
Similar Podcasts
#ExpertAnswers: Christopher Perry and Homira Osman on Integrating Patients, Clinical, and Advocacy Partners with Preclinical Research Labs
Dr. Christopher Perry, York University and Dr. Homira Osman, Muscular Dystrophy Canada answer questions from a recent webinar on how the integration of clinical, industrial, and not-for-profit advocacy partners with preclinical research labs offers great potential to improve our research impact.
#ExpertAnswers: Sarah Greising on Muscle Injury Recovery
Sarah Greising discusses the current pathophysiologic understanding of the skeletal muscle remaining following traumatic musculoskeletal injuries.
#ExpertAnswers: Bradley Palmer on Measuring Cardiac Tissue
Bradley Palmer answers questions from a recent webinar where he highlighted and demonstrated the challenging preparation of cardiac tissue slices and measurement of force and calcium.
Related Content
Molecular Signals Mediating Increases in Muscle Size and Function
In this webinar, Dr. Bert Blaauw elucidates skeletal muscle regulatory pathways and offers approaches to tackle muscle deficits for therapy.
Control of Muscle Glucose Uptake in vivo: Thinking Outside the Myocyte
In this webinar, David Wasserman, PhD provides a more complete understanding of muscle glucose uptake through consideration of the integration of physiological systems that control this process.
Cut and Paste of Myosin Binding Protein-C in Striated Muscles
Dr. Samantha Harris discusses the development of three new mouse models in her lab, engineered to target and replace specific myosin binding protein-C paralogs in muscle fibers and impact of their mutations on skeletal and cardiac muscle diseases.